| Reference number |  |
|------------------|--|
| 1759-H           |  |

## SPECIALTY QUANTITY LIMIT PROGRAM

NEULASTA (pegfilgrastim) FULPHILA (pegfilgrastim-jmdp) UDENYCA (pegfilgrastim-cbqv)

## I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

## **II. COVERED QUANTITIES**

| Medication   | Standard Limit | FDA-Recommended dosing   |
|--|----------------|--|
| Neulasta/Fulphila/Udenyca<br>(pegfilgrastim) injection 6 mg<br>per 0.6 mL solution | 2 per 28 days  | Patients with cancer receiving myelosuppressive chemotherapy:  • 6 mg subcutaneously once per chemotherapy cycle  • Pediatric patients: Based on body weight not to exceed adult doses |

## **III. REFERENCES**

- 1. Neulasta [package insert]. Thousand Oaks, CA: Amgen Inc.; June 2018.
- 2. Fulphila [package insert]. Zurich, Switzerland: Mylan; June 2018.
- 3. Udenyca [package insert]. Redwood City, California: Coherus BioSciences, Inc: November 2018.

Specialty Quantity Limit Neulasta-Fulphila-Udenyca P2018a.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2018 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of